 |
42 Diseases |  |
114 Trials |
|
114 Trials |  |
1654 News |  |
| «12...19202122232425262728293031» |
- | Rituxan (rituximab) / Roche
Trial completion, Combination therapy: Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Sep 25, 2013
P1/2, N=42, Completed, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed
- |||||| Enrollment open, Monotherapy, Metastases: A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Sep 19, 2013
P3, N=670, Recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Rituxan (rituximab) / Roche
Enrollment change: Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment (clinicaltrials.gov) - Sep 18, 2013
P2, N=9, Terminated, Sponsor: Roswell Park Cancer Institute
Not yet recruiting --> Recruiting N=39 --> 9
- || iniparib (BSI 201) / Sanofi
Enrollment closed, Combination therapy, PARP Biomarker: A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors (clinicaltrials.gov) - Sep 13, 2013
P1, N=160, Active, not recruiting, Sponsor: Sanofi
N=39 --> 9 Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
Enrollment closed, Metastases: Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer (clinicaltrials.gov) - Aug 22, 2013
P2, N=50, Active, not recruiting, Sponsor: University of Medicine and Dentistry New Jersey
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Votrient (pazopanib) / Novartis, BeiGene
Enrollment change, Metastases: Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma (clinicaltrials.gov) - Aug 14, 2013
P1/2, N=19, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Recruiting --> Active, not recruiting N=54 --> 19
- |||||| Enrollment open: A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy (clinicaltrials.gov) - Aug 13, 2013
P3, N=120, Recruiting, Sponsor: Xian-Janssen Pharmaceutical Ltd.
N=54 --> 19 Not yet recruiting --> Recruiting
- Enrollment closed: AMVAC: Dose Dense MVAC for Muscle Invasive Bladder Cancer (clinicaltrials.gov) - Aug 13, 2013
P2, N=42, Active, not recruiting, Sponsor: Fox Chase Cancer Center
Not yet recruiting --> Recruiting Suspended --> Active, not recruiting
- |||| veliparib (ABT-888) / AbbVie
Trial completion, Combination therapy: A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer (clinicaltrials.gov) - Jul 21, 2013
P2, N=168, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Suspended --> Active, not recruiting Active, not recruiting --> Completed
- motolimod (VTX 2337) / BMS
Enrollment closed, Combination therapy: TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer (clinicaltrials.gov) - Jul 17, 2013
P1, N=36, Active, not recruiting, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Istodax (romidepsin) / Astellas, BMS
New P1 trial, Combination therapy, Epigenetic controller: Phase I Dose-finding and Preliminary Efficacy Study of the Istodax (clinicaltrials.gov) - Jul 16, 2013
P1, N=24, Not yet recruiting, Sponsor: Weiyun Ai
- pegylated liposomal doxorubicin / Generic mfg.
Trial completion: Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer (clinicaltrials.gov) - Jul 16, 2013
P1, N=20, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Duomeisu (pegylated liposomal doxorubicin) / CSPC Pharma, veliparib (ABT-888) / AbbVie
Enrollment open, PARP Biomarker, Metastases: Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer (clinicaltrials.gov) - Jun 30, 2013
P1, N=58, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Suspended --> Recruiting
- Ninlaro (ixazomib) / Takeda
New P1 trial: Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia (clinicaltrials.gov) - Jun 25, 2013
P1, N=18, Recruiting, Sponsor: Ehab L Atallah
- Leukine (sargramostim) / Partner Therap
Trial completion, Combination therapy: Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer (clinicaltrials.gov) - Jun 25, 2013
P1, N=18, Completed, Sponsor: Roswell Park Cancer Institute
Suspended --> Recruiting Active, not recruiting --> Completed
- picoplatin (AMD 473) / Accelerated Pharma
Trial completion, Metastases: ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma (clinicaltrials.gov) - Jun 16, 2013
P1, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM) (clinicaltrials.gov) - Jun 11, 2013
P1/2, N=58, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial termination: Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer (clinicaltrials.gov) - Jun 6, 2013
P1, N=0, Terminated, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed Completed --> Terminated
- Trial termination: Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant (clinicaltrials.gov) - Jun 2, 2013
P2, N=45, Terminated, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated Active, not recruiting --> Terminated; The study was closed early due to weak accrual on June 26, 2012.
- Enrollment open, Metastases: A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer (clinicaltrials.gov) - Jun 2, 2013
P1, N=42, Recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Terminated; The study was closed early due to weak accrual on June 26, 2012. Not yet recruiting --> Recruiting
- Duomeisu (pegylated liposomal doxorubicin) / CSPC Pharma, veliparib (ABT-888) / AbbVie
Trial initiation date, PARP Biomarker, Metastases: Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer (clinicaltrials.gov) - May 14, 2013
P1, N=58, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Initiation date: Feb 2010 --> Jun 2010
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
Trial initiation date, Metastases: Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer (clinicaltrials.gov) - May 14, 2013
P1/2, N=50, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Feb 2010 --> Jun 2010 Initiation date: Oct 2005 --> Jan 2006
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
Enrollment closed, Metastases: Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer (clinicaltrials.gov) - May 14, 2013
P1/2, N=50, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Oct 2005 --> Jan 2006 Recruiting --> Active, not recruiting
- New P2 trial: MYLY: Phase II Study Evaluating a Combination of Pegylated Liposomal Doxorubicin and Dexamethasone for the Treatment of Immunocompetent Patients With Cerebral Lymphoma Relapsed or Refractory to First-line Chemotherapy With High Dose Methotrexate (MTXHD) and / or High-dose Cytarabine. (clinicaltrials.gov) - May 5, 2013
P2, N=25, Recruiting, Sponsor: University Hospital, Brest
- |||||||||| New P3 trial, Monotherapy, Metastases: A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - May 1, 2013
P3, N=670, Recruiting, Sponsor: Janssen Research & Development, LLC
- pegylated liposomal doxorubicin / Generic mfg., lenalidomide / Generic mfg.
Trial completion: Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM) (clinicaltrials.gov) - Apr 29, 2013
P2, N=57, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- veliparib (ABT-888) / AbbVie
Enrollment open: Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer (clinicaltrials.gov) - Apr 28, 2013
P2, N=80, Recruiting, Sponsor: Thomas Jefferson University
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| New P3 trial: A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy (clinicaltrials.gov) - Apr 24, 2013
P3, N=120, Recruiting, Sponsor: Xian-Janssen Pharmaceutical Ltd.
- Trial completion: Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma (clinicaltrials.gov) - Apr 22, 2013
P2, N=46, Completed, Sponsor: Roswell Park Cancer Institute
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||||| Avastin (bevacizumab) / Roche
New P3 trial: ENGOT ov-18: Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer (clinicaltrials.gov) - Apr 21, 2013
P3, N=654, Recruiting, Sponsor: AGO Research GmbH
- Trial suspension, Metastases: Single Dose of Intravenous rhTNF-? and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas (clinicaltrials.gov) - Apr 15, 2013
P1, N=21, Suspended, Sponsor: Ludwig Institute for Cancer Research
Active, not recruiting --> Completed Not yet recruiting --> Suspended
- pegylated liposomal doxorubicin / Generic mfg.
Trial termination: Liposomal Doxorubicin in Treating Patients With Persistent or Recurrent Cancer of the Cervix (clinicaltrials.gov) - Apr 9, 2013
P2, N=0, Terminated, Sponsor: Gynecologic Oncology Group
Not yet recruiting --> Suspended Completed --> Terminated
- pegylated liposomal doxorubicin / Generic mfg.
Trial completion: Liposomal Doxorubicin Plus Combination Chemotherapy in Treating Patients With AIDS-Associated Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Apr 9, 2013
P1, N=48, Completed, Sponsor: University of Alabama at Birmingham
Completed --> Terminated Active, not recruiting --> Completed
- | veliparib (ABT-888) / AbbVie
New P2 trial: Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer (clinicaltrials.gov) - Mar 24, 2013
P2, N=80, Recruiting, Sponsor: Thomas Jefferson University
- | New P1 trial, Metastases: A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer (clinicaltrials.gov) - Mar 19, 2013
P1, N=42, Recruiting, Sponsor: Janssen Research & Development, LLC
- pegylated liposomal doxorubicin / Generic mfg., carfilzomib / Generic mfg.
Clinical: Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Mar 17, 2013
P1/2, N=53, Recruiting, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Initiation date: Jun 2011 --> May 2012
- KHK 2866 / Kyowa Kirin
Trial termination, Combination therapy, Monotherapy, Metastases: Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer (clinicaltrials.gov) - Mar 4, 2013
P1, N=22, Terminated, Sponsor: Kyowa Hakko Kirin Pharma, Inc.
Initiation date: Jun 2011 --> May 2012 Suspended --> Terminated; The study was stopped due to the inability to determine an acceptable dose with the potential for further study
- KHK 2866 / Kyowa Kirin
Enrollment change, Combination therapy, Monotherapy, Metastases: Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer (clinicaltrials.gov) - Mar 4, 2013
P1, N=22, Terminated, Sponsor: Kyowa Hakko Kirin Pharma, Inc.
Suspended --> Terminated; The study was stopped due to the inability to determine an acceptable dose with the potential for further study N=123 --> 22
- |||| Vynfinit (vintafolide) / Novartis
Trial completion, Combination therapy: PRECEDENT: Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04) (clinicaltrials.gov) - Mar 4, 2013
P2, N=162, Completed, Sponsor: Merck Sharp & Dohme Corp.
N=123 --> 22 Active, not recruiting --> Completed
- || Avastin (bevacizumab) / Roche
New P3 trial: ENGOT-ov 17: Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer (clinicaltrials.gov) - Feb 27, 2013
P3, N=400, Recruiting, Sponsor: National Cancer Institute, Naples
- Trial termination, Metastases: ErbB2 Positive Metastatic Breast Cancer (clinicaltrials.gov) - Feb 25, 2013
P1/2, N=15, Terminated, Sponsor: China Medical University Hospital
Active, not recruiting --> Completed Recruiting --> Terminated
- pegylated liposomal doxorubicin / Generic mfg., lenalidomide / Generic mfg.
Enrollment change: Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM) (clinicaltrials.gov) - Feb 12, 2013
P2, N=57, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting --> Terminated N=20 --> 57
- pegylated liposomal doxorubicin / Generic mfg., epirubicin / Generic mfg.
Trial termination, Metastases: Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer (clinicaltrials.gov) - Feb 11, 2013
P2, N=100, Terminated, Sponsor: Hellenic Oncology Research Group
N=20 --> 57 Suspended --> Terminated; Due to poor accrual
- pegylated liposomal doxorubicin / Generic mfg., epirubicin / Generic mfg.
Enrollment change, Metastases: Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer (clinicaltrials.gov) - Feb 11, 2013
P2, N=100, Terminated, Sponsor: Hellenic Oncology Research Group
Suspended --> Terminated; Due to poor accrual N=182 --> 100
- Enrollment change, PARP Biomarker: Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (clinicaltrials.gov) - Jan 30, 2013
P1, N=66, Recruiting, Sponsor: National Cancer Institute (NCI)
N=182 --> 100 N=48 --> 66
- pegylated liposomal doxorubicin / Generic mfg.
Enrollment change, Surgery, Metastases: Pegylated Liposomal Doxorubicin and Docetaxel in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery (clinicaltrials.gov) - Jan 30, 2013
P2, N=6, Terminated, Sponsor: Roswell Park Cancer Institute
N=48 --> 66 N=36 --> 6
- ||| Arenegyr (NGR-hTNF) / AGC Biologics
Enrollment change, Combination therapy: Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer (clinicaltrials.gov) - Jan 27, 2013
P2, N=124, Recruiting, Sponsor: MolMed S.p.A.
N=36 --> 6 N=100 --> 124
- pegylated liposomal doxorubicin / Generic mfg., gemcitabine / Generic mfg.
Enrollment change, Metastases: Phase II Clinical Trial of Gemcitabine and Doxil (clinicaltrials.gov) - Jan 16, 2013
P2, N=19, Completed, Sponsor: University of Pittsburgh
N=100 --> 124 N=40 --> 19
- | Trial initiation date, Metastases: Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma (clinicaltrials.gov) - Jan 8, 2013
P3, N=240, Completed, Sponsor: National Cancer Institute (NCI)
N=40 --> 19 Initiation date: Nov 1998 --> Mar 1999
- | Trial completion, Metastases: Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma (clinicaltrials.gov) - Jan 8, 2013
P3, N=240, Completed, Sponsor: National Cancer Institute (NCI)
Initiation date: Nov 1998 --> Mar 1999 Active, not recruiting --> Completed